News
-
-
-
PRESS RELEASE
Cherry SE publishes preliminary results for the third quarter of 2025 – Focus remains on cost reduction and liquidity management
Cherry SE releases preliminary financial results for Q3 2025, showcasing revenue growth and improved EBITDA margin through cost reduction and liquidity management -
-
-
PRESS RELEASE
BioNxt Reports "Readiness to Grant" Patent Notification from the Eurasian Patent Organization
BioNxt Solutions Inc. receives "Readiness to Grant" notification from EAPO for comprehensive patent application on sublingual delivery of anticancer drugs for autoimmune neurodegenerative diseases, including lead product BNT23001 for MS treatment. Patent protection strengthens commercialization strategy -
-
-
-
